विवरण
Liquid biopsies represent a groundbreaking advancement in cancer detection, offering a non-invasive alternative to traditional tissue biopsies. These tests analyze circulating tumor DNA (ctDNA) or other biomarkers in blood to identify genetic mutations or alterations associated with cancer. Liquid biopsies provide a real-time snapshot of the tumor's genetic profile, aiding in early cancer detection, monitoring treatment response, and detecting minimal residual disease. This revolutionary approach holds promise for personalized medicine, allowing for more precise and timely interventions, ultimately transforming the landscape of cancer diagnosis and management.
सारांश
- Liquid biopsy is an evolving technique that aims to replace traditional tissue biopsies in cancer management. Tissue biopsies involve cutting a piece of solid tissue for examination, while liquid biopsies primarily use blood samples (or other body fluids) to detect cancer-related materials. One major problem with tissue biopsy is tumor heterogeneity, where different parts of a tumor have different genetic makeups.
- Tumor heterogeneity can be intratumoral (within the tumor itself) or intertumoral (between the primary tumor and metastases). Resistance to therapy can also arise from genetic mechanisms, which may differ from the initial tumor. Traditional re-biopsies are often needed to understand resistance, but they come with complications like pneumothorax or hemorrhage.
- Cell-free DNA (cfDNA) is isolated from blood samples in liquid biopsies. This cfDNA contains normal DNA, tumor DNA, fetal DNA (in pregnant women), and donor DNA (in transplant patients). Liquid biopsy is particularly useful in advanced-stage cancers, where tumor cells are more likely to be released into the blood. Certain cancers, like lung, colorectal, and endometrial cancers, are well-suited for liquid biopsies.
- While tissue biopsies allow for histological diagnosis and staging, liquid biopsies have the potential to detect tumor heterogeneity and can be performed more frequently. However, liquid biopsies lack standardization and guidelines are not yet fully incorporated. Certain tests, like PD-L1 assessment, still require tissue biopsy. Liquid biopsies offer the potential for faster processing and quicker treatment initiation.
- International guidelines have approved certain mutations detectable in liquid biopsy, considering them as reliable as tissue biopsy for those specific mutations. Liquid biopsies have shown impressive overall response rates and disease control rates based on identified mutations. Key considerations when choosing a liquid biopsy platform include analytical and clinical validation, accreditation of the lab, regulatory approvals, and documented response rates.
- Liquid biopsy, though currently costly for broad implementation, holds the promise of revolutionizing cancer treatment. It can provide a more complete tumor profile when combined with tissue biopsy. It reduces the need for repeat tissue biopsies and accelerating the time to treatment.
नमूना प्रमाण पत्र
वक्ताओं के बारे में
डॉ. श्रीनाथ भारद्वाज
कंसल्टेंट, मेडिकल ऑन्कोलॉजी और हेमेटोलॉजी, अपोलो कैंसर इंस्टीट्यूट, जुबली हिल्स, हैदराबाद
वित्तीय प्रकटीकरण
टिप्पणियाँ
टिप्पणियाँ
टिप्पणी करने के लिए आपको लॉगिन होना होगा।